Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Breakthrough T1D-funded researcher wins Nobel Prize
Professor Baker’s Nobel Prize acknowledges his work in discovering a way to create new proteins that have never existed before. These proteins can potentially be used to treat conditions like type 1 diabetes (T1D).
Proteins are made up of various combinations of 20 different ‘building blocks’ called amino acids. In 2003, Professor Baker succeeded in using these building blocks to design a completely unique protein. Since then, his team of researchers have continued to create imaginative new proteins which can be used as medicines, vaccines, and tiny sensors.
In 2016, we recognised the potential application of this to T1D and awarded Professor Baker two grants, funding him to use a computer model to create new, glucose-responsive insulin (GRI). He designed a tiny glucose-responsive protein that can be added to existing long-acting forms of insulin to give them the ability to turn on at high glucose levels and off again once they are lowered.
GRIs are a type of novel (new) insulin, which can detect and respond to changing blood glucose levels, which could help relieve the burden of glucose monitoring. GRI is designed to be administered, lay waiting in the blood stream, and only be active when it is needed.
They are still at an early stage of development, but we’re funding researchers, like Professor Baker, to develop the next generation of insulins. Baker’s grant was one of many projects we are pursuing in GRI.
Through the Type 1 Diabetes Grand Challenge, our partnership with the Steve Morgan Foundation and Diabetes UK, we are investing £15 million in research to develop novel insulins. This includes GRIs, ultra-fast acting insulins, and any other new type of insulin that makes managing type 1 diabetes easier.
We are funding six researchers around the world to drive forward their novel insulin designs. Four of these researchers are developing GRIs, another is making a rapid acting insulin, and another is combining the hormones insulin and glucagon in one molecule.
These prestigious awards celebrate outstanding contributions in Peace, Literature, Physics, Chemistry, Physiology or Medicine, and Economic Sciences. The Prizes go to the best and brightest people with the most innovative and revolutionary ideas.
That this year’s Nobel Prize for Chemistry recognises a researcher and concept that we have previously funded demonstrates that we are funding some of the very best scientists in the world. Professor Baker shares this Prize with two other scientists who used artificial intelligence to work out the structure of proteins.
The 2024 Nobel Prize in Physiology or Medicine was awarded to two other researchers who have discovered microRNA, which regulates which genes are switched on. Breakthrough T1D is currently funding research into microRNA and its potential uses in T1D.
Learn more about the next generation of insulins, known as novel insulins.
Find out about our research to cure, treat and prevent type 1 diabetes.
Discover the research projects we are currently funding in the UK
A recent study has shown that a treatment currently used for type 2 diabetes could be used to help prevent kidney damage in young adults with type 1
New data from Sana Biotechnology, in collaboration with Uppsala University Hospital in Sweden, shows that six months post-transplant, one person with type 1 diabetes (T1D) is successfully producing insulin and does not require immunosuppression.
US-based company Vertex have published promising figures from their cell therapy trial, showing advancements in stem cell research.
We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
